Last reviewed · How we verify
Live attenuated tetravalent dengue vaccine — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Live attenuated tetravalent dengue vaccine (Live attenuated tetravalent dengue vaccine) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Live attenuated tetravalent dengue vaccine TARGET | Live attenuated tetravalent dengue vaccine | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Live attenuated tetravalent dengue vaccine CI watch — RSS
- Live attenuated tetravalent dengue vaccine CI watch — Atom
- Live attenuated tetravalent dengue vaccine CI watch — JSON
- Live attenuated tetravalent dengue vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Live attenuated tetravalent dengue vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/live-attenuated-tetravalent-dengue-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab